{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:42:42Z","timestamp":1792208562165,"version":"4.4.0"},"reference-count":81,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR159924"],"award-info":[{"award-number":["NIHR159924"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n Glucagon-like peptide 1 receptor agonists are a class of drug originally developed to treat type 2 diabetes but now increasingly used for weight loss, especially in people living with obesity. Despite an abundance of evidence about the effectiveness and safety of glucagon-like peptide 1 receptor agonists for weight loss, network meta-analyses are inconsistent in their quality and scope, and this is a fast-moving field.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n We sought to identify the most recent network meta-analyses evaluating the effectiveness of glucagon-like peptide 1 receptor agonists for weight loss; critically appraise included network meta-analyses; provide an overview of the quality and findings of existing network meta-analyses, and identify any pertinent gaps in the evidence; and consider the value of updating the most recent, comprehensive and high-quality network meta-analyses.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n On 6 June 2023, we searched MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews and Epistemonikos for systematic reviews with network meta-analyses published since 2020 in adults (18 or above) with body mass index \u2265\u200525 (or \u2265\u200523 for Asian populations), including at least one relevant glucagon-like peptide 1 receptor agonist and weight loss outcomes. We screened and selected reviews in duplicate and independently, and appraised reviews using a modified A MeaSurement Tool to Assess systematic Reviews 2 (AMSTAR-2)\u00a0and a network meta-analysis reliability checklist. The highest-quality reviews were then extracted in depth, and the most relevant network meta-analysis models identified, focusing on weight loss and safety outcomes. A top-up search for trials published since October 2022 was also undertaken to identify relevant trials not included in published network meta-analyses. A further search for new network meta-analyses was conducted on 26 September 2024.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 22 systematic reviews identified, 14 were prioritised for analysis as the remaining 8 reviews were rated as low or critically low quality. We focused on network meta-analyses of weight loss outcomes measured at 6 months, 12 months, longer than 12 months or over a mix of time points. At 6 months, subcutaneous tirzepatide was the most effective drug associated with 9\u00a0kg (at 5\u00a0mg) to 12\u00a0kg (at 15\u00a0mg) of weight loss. However, the largest effects were seen for subcutaneous semaglutide 2.4\u00a0mg, which was associated with between 11.5 and 12.5\u00a0kg of weight loss, though this came from two network meta-analyses, both informed by six trials, and both merging findings across multiple time points. The relative effectiveness among glucagon-like peptide 1 receptor agonists followed a pattern suggested by their performance against placebo, with tirzepatide and semaglutide standing out as the most effective drugs for weight loss. No network meta-analyses compared tirzepatide and semaglutide 2.4\u00a0mg. The drugs associated with the greatest weight loss, tirzepatide and semaglutide 2.4\u00a0mg, were generally associated with increased risk of safety issues compared to placebo. The update trial search identified 11 new trials, which, though largely small, could make a new network meta-analysis useful. The update search for network meta-analyses yielded 13 new includes. Among other novel comparisons, tirzepatide was indirectly compared with semaglutide 2.4\u00a0mg, outperforming it at 15\u00a0mg, but not 5 or 10\u00a0mg. Data again came from merged time points.<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n To our knowledge, this is the first review of network meta-analyses of glucagon-like peptide 1 receptor agonists. The evidence presented regarding weight loss is in general agreement with the wider literature, though data on tirzepatide were not as resounding as reported in some meta-analyses.<\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Current network meta-analyses of glucagon-like peptide 1 receptor agonists with weight loss outcomes often lack clarity about the network meta-analysis methods, such as which trials were included. The tendency to combine multiple doses of drugs, and to merge findings from multiple time points, limits our understanding of dose and time effects.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Head-to-head trials of tirzepatide versus semaglutide 2.4\u00a0mg are required to determine their relative effectiveness and safety, as the two most promising options for weight loss, as are longer-term trials to establish the effectiveness and safety of glucagon-like peptide 1 receptor agonists when taken for durations of >\u200572 weeks.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n This article presents independent research funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme as award number NIHR159924.<\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/skht8119","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T09:03:01Z","timestamp":1733475781000},"page":"1-73","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-0911","authenticated-orcid":true,"given":"Michael","family":"Nunns","sequence":"first","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4944-664X","authenticated-orcid":true,"given":"Samantha","family":"Febrey","sequence":"additional","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1533-6862","authenticated-orcid":true,"given":"Jill","family":"Buckland","sequence":"additional","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-4484","authenticated-orcid":true,"given":"Rebecca","family":"Abbott","sequence":"additional","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8379-8198","authenticated-orcid":true,"given":"Rebecca","family":"Whear","sequence":"additional","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0963-9201","authenticated-orcid":true,"given":"Alison","family":"Bethel","sequence":"additional","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9135-5488","authenticated-orcid":true,"given":"Kate","family":"Boddy","sequence":"additional","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6092-5019","authenticated-orcid":true,"given":"Liz","family":"Shaw","sequence":"additional","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-0234","authenticated-orcid":true,"given":"Jo Thompson","family":"Coon","sequence":"additional","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9823-4790","authenticated-orcid":true,"given":"GJ","family":"Melendez-Torres","sequence":"additional","affiliation":[{"name":"Isca Evidence, University of Exeter Medical School, Faculty of Health & Life Sciences, University of Exeter, Exeter, Devon, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,6]]},"reference":[{"key":"key2026090817593900_ref1-bib1","volume-title":"Factsheet: Obesity and Overweight","author":"World Health Organization","year":"2021"},{"key":"key2026090817593900_ref2-bib2","volume-title":"Statistics on Obesity, Physical Activity and Diet, England, 2020","author":"NHS Digital","year":"2020"},{"key":"key2026090817593900_ref3-bib3","volume-title":"Policy Paper: Tackling Obesity: Empowering Adults and Children to Live Healthier Lives","author":"Department of Health and Social Care","year":"2020"},{"key":"key2026090817593900_ref4-bib4","doi-asserted-by":"crossref","first-page":"R200","DOI":"10.1530\/EC-21-0130","article-title":"How glucagon-like peptide 1 receptor agonists work","volume":"10","author":"Andreasen","year":"2021","journal-title":"Endocr Connect"},{"key":"key2026090817593900_ref5-bib5","volume-title":"Tirzepatide for Treating Type 2 Diabetes. Technology Appraisal Guidance [TA924]","author":"National Institute for Health and Clinical Excellence","year":"2023"},{"key":"key2026090817593900_ref6-bib6","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"key2026090817593900_ref7-bib7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","article-title":"Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC good practice task force report","volume":"17","author":"Jansen","year":"2014","journal-title":"Value Health"},{"key":"key2026090817593900_ref8-bib8","first-page":"MR000028","article-title":"How effects on health equity are assessed in systematic reviews of interventions","volume":"1","author":"Welch","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026090817593900_ref9-bib9","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"key2026090817593900_ref10-bib10","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/dom.14291","article-title":"Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: a systematic review and network meta-analysis","volume":"23","author":"Avgerinos","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"key2026090817593900_ref11-bib11","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/healthcare9091125","article-title":"Weekly Semaglutide vs. Liraglutide efficacy profile: a network meta-analysis","volume":"9","author":"Alsugair","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"key2026090817593900_ref12-bib12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/dom.14008","article-title":"Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis","volume":"22","author":"Hussein","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"key2026090817593900_ref13-bib13","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1111\/dom.15138","article-title":"Clinical outcomes associated with drugs for obesity and overweight: a systematic review and network meta-analysis of randomized controlled trials","volume":"25","author":"Iannone","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"key2026090817593900_ref14-bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s13300-020-00975-y","article-title":"Comparative efficacy of dual and single initiation of add-on oral antihyperglycemic agents in type 2 diabetes uncontrolled on metformin alone: a systematic literature review and network meta-analysis","volume":"12","author":"Lautsch","year":"2021","journal-title":"Diabetes Ther"},{"key":"key2026090817593900_ref15-bib15","doi-asserted-by":"crossref","first-page":"649018","DOI":"10.3389\/fendo.2021.649018","article-title":"Efficacy of various hypoglycemic agents in the treatment of patients with nonalcoholic liver disease with or without diabetes: a network meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key2026090817593900_ref16-bib16","doi-asserted-by":"crossref","first-page":"e061807","DOI":"10.1136\/bmjopen-2022-061807","article-title":"Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis","volume":"13","author":"Ma","year":"2023","journal-title":"BMJ Open"},{"key":"key2026090817593900_ref17-bib17","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"key2026090817593900_ref18-bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3350\/cmh.2022.0330","article-title":"Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis","volume":"29","author":"Park","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"key2026090817593900_ref19-bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"key":"key2026090817593900_ref20-bib20","doi-asserted-by":"crossref","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"BMJ"},{"key":"key2026090817593900_ref21-bib21","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/dom.14451","article-title":"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"23","author":"Tsapas","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"key2026090817593900_ref22-bib22","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/CLEP.S391819","article-title":"Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review","volume":"14","author":"Xie","year":"2022","journal-title":"Clin Epidemiol"},{"key":"key2026090817593900_ref23-bib23","doi-asserted-by":"crossref","first-page":"102511","DOI":"10.1016\/j.dsx.2022.102511","article-title":"Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes","volume":"16","author":"Zaazouee","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"key2026090817593900_ref24-bib24","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S0140-6736(24)00351-9","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"403","author":"Shi","year":"2024","journal-title":"Lancet"},{"key":"key2026090817593900_ref25-bib25","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1007\/s13300-021-01034-w","article-title":"Once-daily oral semaglutide versus injectable GLP-1 RAs in people with type 2 diabetes inadequately controlled on basal insulin: systematic review and network meta-analysis","volume":"12","author":"Chubb","year":"2021","journal-title":"Diabetes Ther"},{"key":"key2026090817593900_ref26-bib26","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.2147\/DMSO.S392952","article-title":"Semaglutide 2.4 Mg for the management of overweight and obesity: systematic literature review and meta-analysis","volume":"15","author":"Smith","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"key2026090817593900_ref27-bib27","doi-asserted-by":"crossref","first-page":"e13543","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"key":"key2026090817593900_ref28-bib28","doi-asserted-by":"crossref","first-page":"998816","DOI":"10.3389\/fphar.2022.998816","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis","volume":"13","author":"Guan","year":"2022","journal-title":"Front Pharmacol"},{"key":"key2026090817593900_ref29-bib29","doi-asserted-by":"crossref","first-page":"101213","DOI":"10.1016\/j.eclinm.2021.101213","article-title":"Association of Glucagon-like Peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis","volume":"42","author":"Vosoughi","year":"2021","journal-title":"EClinicalMedicine"},{"key":"key2026090817593900_ref30-bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/1573399816666200705210006","article-title":"Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus","volume":"17","author":"Ida","year":"2021","journal-title":"Curr Diabetes Rev"},{"key":"key2026090817593900_ref31-bib31","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1007\/s12325-021-01637-6","article-title":"Efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes mellitus: a network meta-analysis","volume":"38","author":"Jiang","year":"2021","journal-title":"Adv Ther"},{"key":"key2026090817593900_ref32-bib32","doi-asserted-by":"crossref","first-page":"100944","DOI":"10.1016\/j.conctc.2022.100944","article-title":"The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis","volume":"28","author":"Alhindi","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"key2026090817593900_ref33-bib33","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"key2026090817593900_ref34-bib34","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"key":"key2026090817593900_ref35-bib35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"key2026090817593900_ref36-bib36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key2026090817593900_ref37-bib37","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","article-title":"Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial","volume":"398","author":"Ludvik","year":"2021","journal-title":"Lancet"},{"key":"key2026090817593900_ref38-bib38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"key2026090817593900_ref39-bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/osp4.619","article-title":"A pilot randomized controlled trial of liraglutide 3.0\u2009mg for binge eating disorder","volume":"9","author":"Allison","year":"2023","journal-title":"Obes Sci Pract"},{"key":"key2026090817593900_ref40-bib40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.fertnstert.2022.04.027","article-title":"Liraglutide 3\u2009mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study","volume":"118","author":"Elkind-Hirsch","year":"2022","journal-title":"Fertil Steril"},{"key":"key2026090817593900_ref41-bib41","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"key2026090817593900_ref42-bib42","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet (London, England)"},{"key":"key2026090817593900_ref43-bib43","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2337\/dc22-1710","article-title":"Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes","volume":"46","author":"Heise","year":"2023","journal-title":"Diabetes Care"},{"key":"key2026090817593900_ref44-bib44","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s11325-022-02768-y","article-title":"Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea","volume":"27","author":"Jiang","year":"2022","journal-title":"Sleep Breath"},{"key":"key2026090817593900_ref45-bib45","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50\u2009mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet (London, England)"},{"key":"key2026090817593900_ref46-bib46","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/dom.14903","article-title":"Comparative effects of weight loss and incretin-based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: a randomized controlled trial","volume":"25","author":"Mashayekhi","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"key2026090817593900_ref47-bib47","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","article-title":"Safety and efficacy of liraglutide, 3.0\u2009mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial","volume":"158","author":"Mok","year":"2023","journal-title":"JAMA Surg"},{"key":"key2026090817593900_ref48-bib48","doi-asserted-by":"crossref","first-page":"951570","DOI":"10.3389\/fendo.2022.951570","article-title":"Effects of liraglutide or lifestyle interventions combined with other antidiabetic drugs on abdominal fat distribution in people with obesity and type 2 diabetes mellitus evaluated by the energy spectrum ct: a prospective randomized controlled study","volume":"13","author":"Yu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key2026090817593900_ref49-bib49","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/nu15030556","article-title":"Effects of a dulaglutide plus calorie-restricted diet versus a calorie-restricted diet on visceral fat and metabolic profiles in women with polycystic ovary syndrome: a randomized controlled trial","volume":"15","author":"Zhang","year":"2023","journal-title":"Nutrients"},{"key":"key2026090817593900_ref50-bib50","volume-title":"Guideline for Good Clinical Practice E6(R2)","author":"European Medicines Agency","year":"2016"},{"key":"key2026090817593900_ref51-bib51","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00592-021-01830-7","article-title":"Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: a network meta-analysis","volume":"59","author":"Ding","year":"2022","journal-title":"Acta Diabetol"},{"key":"key2026090817593900_ref52-bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2213-8587(23)00388-1","article-title":"Efficacy and safety of once weekly semaglutide 2.4\u2009mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial","volume":"12","author":"Mu","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key2026090817593900_ref53-bib53","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial","volume":"29","author":"Gao","year":"2023","journal-title":"Nat Med"},{"key":"key2026090817593900_ref54-bib54","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2.4\u2009mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key2026090817593900_ref55-bib55","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41366-023-01321-5","article-title":"Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis","volume":"47","author":"Tan","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"key2026090817593900_ref56-bib56","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00125-021-05529-w","article-title":"The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"key":"key2026090817593900_ref57-bib57","doi-asserted-by":"crossref","first-page":"102640","DOI":"10.1016\/j.dsx.2022.102640","article-title":"Efficacy and safety of tirzepatide as novel treatment for type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"16","author":"Permana","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"key2026090817593900_ref58-bib58","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41366-023-01337-x","article-title":"Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials","volume":"47","author":"de Mesquita","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"key2026090817593900_ref59-bib59","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-020-01070-z","article-title":"Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","volume":"19","author":"Alfayez","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"key2026090817593900_ref60-bib60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.pcd.2020.08.017","article-title":"Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: a network meta-analysis of large randomized trials","volume":"15","author":"Wei","year":"2021","journal-title":"Prim Care Diabetes"},{"key":"key2026090817593900_ref61-bib61","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"key2026090817593900_ref62-bib62","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13643-023-02323-0","article-title":"The Commercial determinants of health and evidence synthesis (CODES): methodological guidance for systematic reviews and other evidence syntheses","volume":"12","author":"Petticrew","year":"2023","journal-title":"Syst Rev"},{"key":"key2026090817593900_ref63-bib63","doi-asserted-by":"crossref","first-page":"102181","DOI":"10.1016\/j.eclinm.2023.102181","article-title":"Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"64","author":"Caruso","year":"2023","journal-title":"EClinicalMedicine"},{"key":"key2026090817593900_ref64-bib64","doi-asserted-by":"crossref","first-page":"e34122","DOI":"10.1097\/MD.0000000000034122","article-title":"Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: a network meta-analysis","volume":"102","author":"Chen","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"key2026090817593900_ref65-bib65","doi-asserted-by":"crossref","first-page":"618","DOI":"10.7326\/M23-1490","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the american college of physicians","volume":"177","author":"Drake","year":"2024","journal-title":"Ann Intern Med"},{"key":"key2026090817593900_ref66-bib66","doi-asserted-by":"crossref","first-page":"1182037","DOI":"10.3389\/fendo.2023.1182037","article-title":"New anti-diabetic agents for the treatment of non-alcoholic fatty liver disease: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Kongmalai","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key2026090817593900_ref67-bib67","doi-asserted-by":"crossref","first-page":"116150","DOI":"10.1016\/j.biopha.2024.116150","article-title":"Efficacy and safety of GLP-1RAs for people with obesity: a systematic review based on RCT and Bayesian network meta-analysis","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"key2026090817593900_ref68-bib68","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.clinthera.2023.06.003","article-title":"Pharmaceutical therapies for the treatment of obesity: a network meta-analysis","volume":"45","author":"Morsali","year":"2023","journal-title":"Clin Ther"},{"key":"key2026090817593900_ref69-bib69","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/oby.24002","article-title":"Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis","volume":"32","author":"Pan","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"key2026090817593900_ref70-bib70","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/dom.15312","article-title":"Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus","volume":"26","author":"Tsukamoto","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"key2026090817593900_ref71-bib71","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"key2026090817593900_ref72-bib72","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1111\/dom.15725","article-title":"Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: a network meta-analysis of randomized clinical trials","volume":"26","author":"Ayesh","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"key2026090817593900_ref73-bib73","doi-asserted-by":"crossref","first-page":"100284","DOI":"10.1016\/j.metop.2024.100284","article-title":"Comparative efficacy and safety of weekly dulaglutide versus weekly insulin in type 2 diabetes: a network meta-analysis of randomized clinical trials","volume":"22","author":"Ayesh","year":"2024","journal-title":"Metabol Open"},{"key":"key2026090817593900_ref74-bib74","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12916-023-03129-6","article-title":"Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials","volume":"21","author":"Deng","year":"2023","journal-title":"BMC Med"},{"key":"key2026090817593900_ref75-bib75","doi-asserted-by":"crossref","first-page":"156038","DOI":"10.1016\/j.metabol.2024.156038","article-title":"Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials","volume":"161","author":"Xie","year":"2024","journal-title":"Metab Clin Exp"},{"key":"key2026090817593900_ref76-bib76","doi-asserted-by":"crossref","first-page":"107031","DOI":"10.1016\/j.phrs.2023.107031","article-title":"Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis","volume":"199","author":"Ding","year":"2024","journal-title":"Pharmacol Res"},{"key":"key2026090817593900_ref77-bib77","doi-asserted-by":"crossref","first-page":"n1091","DOI":"10.1136\/bmj.n1091","article-title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"key2026090817593900_ref78-bib78","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2.0\u2009mg versus 1.0\u2009mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Frias","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"key2026090817593900_ref79-bib79","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25\u2009mg and 50\u2009mg compared with 14\u2009mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet (London, England)"},{"key":"key2026090817593900_ref80-bib80","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2.4\u2009mg with once-weekly semaglutide 2.4\u2009mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet (London, England)"},{"key":"key2026090817593900_ref81-bib81","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in chinese adults with obesity: the SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao","year":"2024","journal-title":"JAMA"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2048249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/SKHT8119\/SKHT8119.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2048249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:23:40Z","timestamp":1788881020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/published-articles\/SKHT8119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":81,"alternative-id":["10.3310\/SKHT8119"],"URL":"https:\/\/doi.org\/10.3310\/skht8119","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"04-2023","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"12-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"11-2024","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}